Find Enzastaurin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 170364-57-5, Ly317615, Enzastaurin (ly317615), 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione, Ly-317615, 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
Molecular Formula
C32H29N5O2
Molecular Weight
515.6  g/mol
InChI Key
AXRCEOKUDYDWLF-UHFFFAOYSA-N
FDA UNII
UC96G28EQF

Enzastaurin
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
1 2D Structure

Enzastaurin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
2.1.2 InChI
InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)
2.1.3 InChI Key
AXRCEOKUDYDWLF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7
2.2 Other Identifiers
2.2.1 UNII
UC96G28EQF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ly317615.hcl

2.3.2 Depositor-Supplied Synonyms

1. 170364-57-5

2. Ly317615

3. Enzastaurin (ly317615)

4. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione

5. Ly-317615

6. 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione

7. Db102

8. Uc96g28eqf

9. Ly 317615

10. Chembl300138

11. Db-102

12. Dsstox_cid_24029

13. Dsstox_rid_80101

14. Dsstox_gsid_44029

15. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)-piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione

16. 1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-

17. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione

18. 3-(1-methyl-1h-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl}-1h-pyrrole-2,5-dione

19. Enzastaurin [inn]

20. Cas-170364-57-5

21. Unii-uc96g28eqf

22. 3-(1-methyl-1h-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione

23. Le-0014

24. Enzastaurin [mi]

25. Enzastaurin [usan:inn]

26. Enzastaurin,ly317615

27. Enzastaurin [usan]

28. Enzastaurin; Ly317615

29. Enzastaurin [who-dd]

30. Ly317615 - Enzastaurin

31. Schembl678748

32. Gtpl5693

33. Dtxsid5044029

34. Chebi:91368

35. Amy7827

36. Bcpp000241

37. Hms3265m05

38. Hms3265m06

39. Hms3265n05

40. Hms3265n06

41. Hms3654a13

42. Hms3748e03

43. Bcp02703

44. Ex-a1055

45. Who 8426

46. Zinc1494900

47. Tox21_113367

48. Bdbm50128285

49. Mfcd11040980

50. Nsc767124

51. Nsc800096

52. S1055

53. Akos015994764

54. Tox21_113367_1

55. Ac-5900

56. Bcp9000648

57. Ccg-264797

58. Cs-0132

59. Db06486

60. Nsc-767124

61. Nsc-800096

62. Sb16481

63. Ncgc00238452-01

64. Ncgc00238452-02

65. Ncgc00238452-03

66. Ncgc00238452-11

67. Hy-10342

68. Db-064781

69. Ft-0667873

70. Sw219797-1

71. Ec-000.2315

72. 364e575

73. J-510442

74. Q5381479

75. Brd-k79404599-001-01-0

76. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-1h-pyrrole-2,5-

77. 3-(1-methyl-1h-indol-3-yl)-4-[1-(1-pyridin-2-ylmethyl-piperidin-4-yl)-1h-indol-3-yl]-pyrrole-2,5-dione

78. 3-(1-methyl-1h-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl}-2,5-dihydro-1h-pyrrole-2,5-dione

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 515.6 g/mol
Molecular Formula C32H29N5O2
XLogP33.7
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass515.23212518 g/mol
Monoisotopic Mass515.23212518 g/mol
Topological Polar Surface Area72.2 Ų
Heavy Atom Count39
Formal Charge0
Complexity974
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.


5 Pharmacology and Biochemistry
5.1 Mechanism of Action

Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through multiple mechanisms. Preclinical data indicate it may reduce the cell's ability to reproduce (cell proliferation), increase the natural death of the tumor cells (apoptosis), and inhibit tumor- induced blood supply (angiogenesis). Enzastaurin has been shown to inhibit signaling through the PKC-B and PI3K/AKT pathways. These pathways have been shown to be activated in a wide variety of cancers. In addition to glioblastoma, enzastaurin is also being studied in multiple other tumor types, including non-Hodgkin's lymphoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer, and mantle cell lymphoma.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty